3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Status
Active not recruiting
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
3
Conditions
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasm Metastasis
1
Lung Neoplasms
1
Interventions
Cetuximab
44
Oxaliplatin
39
Irinotecan
38
Fluorouracil
36
Capecitabine
36
pembrolizumab
35
Leucovorin
35
Bevacizumab
35
Nivolumab
21
Gemcitabine
17
regorafenib
13
Panitumumab
12
IFL protocol
12
Folfox protocol
12
Cyclophosphamide
12
Pemetrexed
11
Cisplatin
11
tislelizumab
9
Paclitaxel
9
HMPL-013
9
Carboplatin
9
130-nm albumin-bound paclitaxel
8
durvalumab
7
Specimen Handling
7
Docetaxel
7
trametinib
6
Trifluridine
6
Ipilimumab
6
Drug Therapy
6
trifluridine tipiracil drug combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colorectal Neoplasms
×
JDQ443
×
Clear all
NCT05358249
2026-04-14
KontRASt-03
Novartis
Phase 1/2
Active not recruiting
74 enrolled
NCT07468071
2026-04-02
KontRASt-R
Novartis
Phase 1/2
Not yet recruiting
40 enrolled
NCT04699188
2026-03-18
KontRASt-01
Novartis
Phase 1/2
Active not recruiting
344 enrolled